Stroke management

Prasad, Kameshwar; Kaul, Subhash; Maruvada, Padma; Gorthi, Sankar Prasad; Khurana, Dheeraj; Bakshi, Asha

doi:10.4103/0972-2327.83084

Cited by 36 publications

(49 citation statements)

References 102 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients received conventional treatment according to current guidelines, 11 but the treatment arm, in addition, received BMSCs intravenously within 48 hours of random allocation. No medical therapy was delayed or denied because of patient's participation into the study.…”

Section: Methods and Measurementmentioning

confidence: 99%

See 1 more Smart Citation

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke

Prasad¹,

Sharma²,

Garg³

et al. 2014

Stroke

Self Cite

268

253

View full text Add to dashboard Cite

Background and Purpose-Pilot studies have suggested benefit from intravenous administration of bone marrow mononuclear stem cells (BMSCs) in stroke. We explored the efficacy and safety of autologous BMSCs in subacute ischemic stroke. Methods-This was a phase II, multicenter, parallel group, randomized trial with blinded outcome assessment that included 120 patients. Patients with subacute ischemic stroke were randomly assigned to the arm that received intravenous infusion of autologous BMSCs or to control arm. Coprimary clinical efficacy outcomes were Barthel Index score and modified Rankin scale at day 180. Secondary outcomes were change in infarct volume, National

show abstract

Section: Methods and Measurementmentioning

confidence: 99%

“…Those assessing NIHSS were certified by web based NIH Stroke Scale (NIHSS) -English programme. 11 Barthel index was modified to suit Indian patients and validated prior to start of study. Item 9 and 10 of NIHSS was also modified and validated in the Indian Patients.…”

Section: Study Oversight and Quality Control Measuresmentioning

confidence: 99%

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke

Prasad¹,

Sharma²,

Garg³

et al. 2014

Stroke

Self Cite

268

253

View full text Add to dashboard Cite

show abstract

“…[36][37][38][39]42,48,49,[54][55][56][57]62,63 In the other 17 guidelines, the cause of high-CEA-risk was characterized as being because of only reasons related to vascular anatomy and in others as being because of vascular anatomy or medical comorbidities. Nine of these guidelines gave no specific examples of high-CEArisk scenarios [42][43][44][45]48,49,54,57,63 or referred to other guidelines. …”

mentioning

confidence: 99%

“…38 The territory or laterality of such events was specified in 17 guidelines (52%). 28,31,33,34,[36][37][38]41,42,[48][49][50][51]53,59,[61][62][63] …”

mentioning

confidence: 99%

“…Two guidelines 41,46,47 cited the Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy Trial (SAPPHIRE) 79 for defining high-CEA-risk clinical scenarios. Twenty-nine guidelines included specific recommendations for the use of CAS for patients with high-CEA-risk ACS 28,31,32,[35][36][37][38]41,[43][44][45][46][47][55][56][57][58]62,63 or SCS,27,28,[31][32][33][34][35][36][38][39][40][41][42][44][45][46][47][48][49][50][51][52][53][54][55][56]58,[61]…”

mentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Guidelines for the Management of Asymptomatic and Symptomatic Carotid Stenosis

Abbott

Paraskevas

Kakkos

et al. 2015

Stroke

233

212

View full text Add to dashboard Cite

Background and Purpose-We systematically compared and appraised contemporary guidelines on management of asymptomatic and symptomatic carotid artery stenosis. Methods-We systematically searched for guideline recommendations on carotid endarterectomy (CEA) or carotid angioplasty/stenting (CAS) published in any language between January 1, 2008, and January 28, 2015. Only the latest guideline per writing group was selected. Each guideline was analyzed independently by 2 to 6 authors to determine clinical scenarios covered, recommendations given, and scientific evidence used. Results-Thirty-four eligible guidelines were identified from 23 different regions/countries in 6 languages. Of 28 guidelines with asymptomatic carotid artery stenosis procedural recommendations, 24 (86%) endorsed CEA (recommended it should or may be provided) for ≈50% to 99% average-surgical-risk asymptomatic carotid artery stenosis, 17 (61%) endorsed CAS, 8 (29%) opposed CAS, and 1 (4%) endorsed medical treatment alone. For asymptomatic carotid artery stenosis patients considered high-CEA-risk because of comorbidities, vascular anatomy, or undefined reasons, CAS was endorsed in 13 guidelines (46%). Thirty-one of 33 guidelines (94%) with symptomatic carotid artery stenosis procedural recommendations endorsed CEA for patients with ≈50% to 99% average-CEA-risk symptomatic carotid artery stenosis, 19 (58%) endorsed CAS and 9 (27%) opposed CAS. For high-CEA-risk symptomatic carotid artery stenosis because of comorbidities, vascular anatomy, or undefined reasons, CAS was endorsed in 27 guidelines (82%). Guideline procedural recommendations were based only on results of trials in which patients were randomized 12 to 34 years ago, rarely reflected medical treatment improvements and often understated potential CAS hazards. Qualifying terminology summarizing recommendations or evidence lacked standardization, impeding guideline interpretation, and comparison. This systematic review of contemporary international guidelines was performed to compare and appraise recommendations for the management of patients with ACS and SCS (including accessibility, organization, clarity, and consistency) and the evidence used in making these recommendations. Conclusions-This Methods Guideline SearchesGuidelines with recommendations on the use of CEA or CAS or both patients with ACS or SCS or both were sought systematically using popular search engines, bibliographies, and author professional networks. PubMed and ISI Web of Knowledge were searched independently and synchronously by 2 authors on September 9, 2013 (A.L.A., K.I.P.). PubMed was searched using carotid guideline and then stroke guideline in the title, yielding 91 references after duplicate removal. ISI Web of Knowledge was searched using carotid and guideline and then stroke and guideline in the title, yielding 422 references after removal of duplicates, abstracts, reference materials, letters, corrections, meetings, news, and case reports. Wider searches using the words carotid or stroke and guideline in any ...

show abstract

mHealth applications to support caregiver needs and engagement during stroke recovery: A content review

Lobo

Frølich

Kensing

et al. 2020

Research in Nursing & Health

View full text Add to dashboard Cite

Caregiving in stroke results in severe physical, psychological, and social impacts on the caregiver. Over the past few years, researchers have explored the use of mHealth technologies to support healthcare-related activities due to their ability to provide real-time care at any given place or time. The purpose of this content review is to investigate mHealth apps in supporting stroke caregiving engagement based on three aspects: motivation, value, and satisfaction. We searched app stores and repositories for apps related to stroke caregiving published up to September 2020. Extracted apps were reviewed and filtered using inclusion criteria, and then downloaded onto compatible devices to determine eligibility. Results were compared with evidence-based frameworks to identify the ability of these apps in engaging and supporting the caregiver. Forty-seven apps were included in this review that enabled caregivers to support their needs, such as adjustment to new roles and relationships, involvement in care and caring for oneself using several different functionalities. These functionalities include information resources, risk assessment, remote monitoring, data sharing, reminders and so on. However, no single app was identified that focuses on all aspects of stroke caregiving. We also identified several challenges faced by users through their reviews and the factors associated with value and satisfaction. Our findings can add to the knowledge of existing mHealth technologies and their functionalities to support stroke caregiving needs, and the importance of considering user engagement in the design. They can be used by developers and researchers looking to design better mHealth apps for stroke caregiving.

show abstract

Stroke management

Cited by 36 publications

References 102 publications

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke

Systematic Review of Guidelines for the Management of Asymptomatic and Symptomatic Carotid Stenosis

mHealth applications to support caregiver needs and engagement during stroke recovery: A content review

Contact Info

Product

Resources

About